CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Inhaled placebo +3 moredrug
Likely dose
Inhaled alprazolam 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00477451
NCT00477451Phase 2Completed
CompareCT.gov

Investigation of a Single Dose of Staccato™ Alprazolam for Inhalation on Doxapram-Induced Panic Attack in Patients With Panic Disorder

Alexza Pharmaceuticals, Inc.·interventional·Posted May 23, 2007·Updated Jun 16, 2017

In Brief

A Phase 2 clinical trial evaluating Inhaled placebo, Inhaled alprazolam 1 mg, and 2 other interventions for Treatment of Induced Panic Attack. Completed, enrolled 49 participants across 3 sites.

Detailed Summary

We are developing Staccato™ Alprazolam for the treatment of Panic attacks associated with panic disorder. This study will provide an initial assessment of efficacy, and to continue to describe the tolerability and pharmacokinetics, of a single inhaled dose of Staccato Alprazolam on a doxapram-induced panic attack in patients with panic disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment of Induced Panic Attack
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 23, 2007
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.1 years ago

Interventions

Inhaled placebodrug

Inhaled Staccato Alprazolam Placebo

Inhaled alprazolam 1 mgdrug

Inhaled Staccato Alprazolam 1 mg

Inhaled alprazolam 2 mgdrug

Inhaled Staccato Alprazolam 2 mg

IV doxapramdrug

0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo